RxDoctor Payments Data

Lalitha Sunder, MD

Interventional Cardiology · Houston, TXNPI 1851395438

Payments from drug & device makers

$24,594in general payments, 2019–2025

Across 295 payments — averaging $83.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Abbott$2K
  • Boston Scientific$1K
  • Abiomed$1K
  • Amgen$984
  • Shockwave Medical, Inc$876
  • plus $7K from 38 others

What the payments were for

  • Travel & lodging$9,37638%
  • Food & beverage$15,18562%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,594 in reported general payments places this provider in the 70th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$277,248
Medicare patients
644
Services billed
2,736

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban462$576,438
EntrestoSacubitril/Valsartan220$262,177
FarxigaDapagliflozin Propanediol197$236,202
XareltoRivaroxaban95$133,013
Repatha SureclickEvolocumab107$118,890
JardianceEmpagliflozin75$102,308
OzempicSemaglutide38$65,850
NexlizetBempedoic Acid/Ezetimibe55$47,744
MounjaroTirzepatide18$27,919
MultaqDronedarone Hcl12$26,149
Praluent PenAlirocumab20$24,559
Ezetimibe706$19,761
LivaloPitavastatin Calcium17$15,729
Rosuvastatin Calcium889$15,593
NexletolBempedoic Acid11$12,252

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$202$576,438462 claims
NovartisEntresto$508$262,177220 claims
AstraZenecaFarxiga$635$236,202197 claims
Johnson & JohnsonXarelto$649$133,01395 claims
Boehringer IngelheimJardiance$149$102,30875 claims
Novo NordiskOzempic$672$65,85038 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$280$59,99566 claims
Lilly USA, LLCMounjaro$292$27,91918 claims
Sanofi-aventis U.S. LLCMultaq$59$26,14912 claims
Kowa Pharmaceuticals America, Inc.Livalo$14$15,72917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →